Finance

Beta
Lists
Equity sectors
Symbols
Symbols
Price
Change
% Change
Trend
Prev Close
Open
High
Low
Volume
Mkt Cap
SIXB
Materials
SIXB
Materials
SIXB
-0,21%
1 091,51
-2,30
-0,21%
—1 093,811 096,521 100,221 091,51——
SIXC
Communications
SIXC
Communications
SIXC
+0,22%
610,11
+1,34
+0,22%
—608,77608,77612,97608,77——
SIXE
Energy
SIXE
Energy
SIXE
-1,34%
1 237,98
-16,83
-1,34%
—1 254,811 253,011 253,871 226,33——
SIXI
Industrials
SIXI
Industrials
SIXI
-0,93%
1 744,71
-16,40
-0,93%
—1 761,111 764,271 766,881 744,71——
SIXM
Financials
SIXM
Financials
SIXM
-0,37%
640,18
-2,40
-0,37%
—642,58644,87648,48640,18——
SIXR
Staples
SIXR
Staples
SIXR
-0,18%
849,58
-1,55
-0,18%
—851,13855,66858,75845,56——
SIXRE
Real estate
SIXRE
Real estate
SIXRE
-0,23%
217,48
-0,50
-0,23%
—217,98217,98218,65216,88——
SIXT
Technology
SIXT
Technology
SIXT
+1,52%
3 260,69
+48,86
+1,52%
—3 211,833 227,213 268,383 226,55——
SIXU
Utilities
SIXU
Utilities
SIXU
-0,69%
942,45
-6,53
-0,69%
—948,98948,58957,83941,97——
SIXV
Health care
SIXV
Health care
SIXV
-0,52%
1 466,80
-7,72
-0,52%
—1 474,521 479,031 481,041 466,80——
SIXY
Discretionary
SIXY
Discretionary
SIXY
+0,22%
2 397,50
+5,38
+0,22%
—2 392,122 396,952 421,222 382,32——
ATAI:NASDAQ
AtaiBeckley Inc
4,14 USD
-0,60%
(-0,025) 1D
4,11 USD
-0,58% (-0,024)
After hours
Closed: 1-май, 16:00:04 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for ATAI...
Open
4,15 USD
High
4,20 USD
Low
4,08 USD
Mkt. cap
1,52 млд
Avg. vol.
6,58 млн
Volume
2,36 млн
52-wk high
6,72 USD
52-wk low
1,29 USD
EPS
-2,91 USD
Beta
1,57
Shares outstanding
366,92 млн
No. of employees
99
News stories
From sources across the web
Profile
atai Life Sciences is a pharmaceutical company that is developing psychedelics, other hallucinogens, entactogens, and related drugs for treatment of psychiatric conditions. It was founded in 2018 and is headquartered in Berlin, Germany. The company's pharmaceutical candidates include dimethyltryptamine, -midomafetamine, and ibogaine, as well as EGX-121, 5-MeO-DMT, psilocin, inidascamine, deuterated mitragynine, EGX-A, EGX-B, deuterated etifoxine, and arketamine. In June 2021, atai became a public company when it completed an initial public offering by listing its shares on the NASDAQ stock exchange. In January 2023, atai Life Science's leading drug candidate at the time, arketamine, failed to meet its primary endpoint in a clinical trial. Following that, the company laid off 30% of its staff. Peter Thiel is a major investor in the company. atai Life Sciences has a 22.4% stake in Compass Pathways. Wikipedia
About AtaiBeckley Inc
CEOFlorian Brand
Employees99
Founded2018
Headquarters-
SectorPharmaceutical industry
Websiteataibeckley.com
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
2025-ж. мар.
2025-ж. июн.
2025-ж. сен.
2025-ж. дек.
Revenue
1,56 млн
719,00 миң
749,00 миң
1,07 млн
Cost of goods sold
10,84 млн
10,51 млн
14,68 млн
10,91 млн
Cost of revenue
10,84 млн
10,51 млн
14,68 млн
10,91 млн
Research and development expenses
-
582,00 миң
-
4,00 млн
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
9,99 млн
14,90 млн
14,50 млн
24,40 млн
Operating expense
9,99 млн
15,48 млн
14,50 млн
28,41 млн
Total operating expenses
20,82 млн
25,99 млн
29,18 млн
39,32 млн
Operating income
-19,27 млн
-25,27 млн
-28,44 млн
-38,25 млн
Other non operating income
-13,01 млн
-6,33 млн
-51,25 млн
13,99 млн
EBT including unusual items
-26,34 млн
-27,68 млн
-61,00 млн
-544,84 млн
EBT excluding unusual items
-32,54 млн
-30,16 млн
-79,20 млн
-23,71 млн
Income tax expense
128,00 миң
65,00 миң
102,00 миң
3,00 миң
Effective tax rate
-0,49%
-0,23%
-0,17%
-
Other operating expenses
-
-
-
-
Net income
-26,43 млн
-27,73 млн
-61,07 млн
-544,81 млн
Net profit margin
-1 699,74%
-3 856,61%
-8 154,07%
-51 108,16%
Earnings per share
-0,15
-0,14
-0,28
-1,73
Interest and investment income
186,00 миң
248,00 миң
504,00 миң
542,00 миң
Interest expense
-900,00 миң
-264,00 миң
-
-
Net interest expenses
-714,00 миң
-16,00 миң
504,00 миң
542,00 миң
Depreciation and amortization charges
-
-
-
-
EBITDA
-19,05 млн
-25,05 млн
-28,20 млн
-37,91 млн
Gain or loss from assets sale
-
-
-
692,00 миң
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

My tasks
You haven't created a task yet
Your tasks will appear here. Schedule tasks and put Google Finance to work while you're away.
Templates
Watchlist briefing
A daily pre-market analysis of your watchlist
Upcoming Earnings
Upcoming earnings reports in the week
Abnormal Volatility & Volume
Volatility and volume early warning today
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer